ProCE Banner Activity

Experts Answer Frequently Asked Questions on Melanoma Management

Clinical Thought
Experts answer frequently asked questions on the management of melanoma, including adjuvant therapy selection, considerations for frontline treatment, and biomarker testing.

Released: March 03, 2021

Expiration: March 02, 2022

No longer available for credit.

Share

Faculty

Michael A. Davies

Michael A. Davies, MD, PhD

Professor and Chair, Department of Melanoma Medical Oncology
Professor, Translational Molecular Pathology and Genomic Medicine
Anne and John Mendelsohn Chair in Cancer Research
University of Texas, MD Anderson Cancer Center
Houston, Texas

Ahmad Tarhini

Ahmad Tarhini, MD, PhD

Assistant Professor of Medicine
Department of Medicine/Hematology-Oncology
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Michael A. Davies, MD, PhD

Professor and Chair, Department of Melanoma Medical Oncology
Professor, Translational Molecular Pathology and Genomic Medicine
Anne and John Mendelsohn Chair in Cancer Research
University of Texas, MD Anderson Cancer Center
Houston, Texas

Michael A. Davies, MD, PhD, has disclosed that he has received consulting fees from Apexigen, Array, Bristol-Myers Squibb, Novartis, and Roche/Genentech.

Ahmad Tarhini, MD, PhD

Assistant Professor of Medicine
Department of Medicine/Hematology-Oncology
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Ahmad Tarhini, MD, PhD, has disclosed that he has received funds for research support from Clinigen and OncoSec and consulting fees from Bristol-Myers Squibb, Clinigen, Eisai, Genentech/Roche, Merck, Novartis, and Partner Therapeutics.